SBRT for the Treatment of Isolated Local Recurrence of Resected Pancreatic Cancer
L.K. Morris(Mayo Clinic in Arizona), Christopher L. Hallemeier(Mayo Clinic in Arizona), Jason K. Viehman(Mayo Clinic), Samuel J. Kerans(University of Maryland, Baltimore), Shane S. Neibart(Rutgers, The State University of New Jersey), Jason K. Molitoris(University of Maryland, Baltimore), Salma K. Jabbour(Rutgers, The State University of New Jersey), William F. Regine(University of Kentucky), Krishan R. Jethwa(Mayo Clinic), Daniel T. Chang(National Tsing Hua University), Kimberly L. Johung(Yale University), J.R.M. Baclay(Stanford Cancer Institute)
International Journal of Radiation Oncology*Biology*Physics
October 25, 2021
Cited by 1
Related Papers
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases
|International Journal of Radiation Oncology*Biology*Physics|2002|508
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer
|Annals of Surgery|2019|445
Oesophageal cancer
|The Lancet|2024|265